Contract Pharma Staff10.08.20
Pharm-Olam, a global clinical research organization (CRO), has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, to join its Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures (MCMs).
Pharm-Olam's contract with BARDA is an indefinite-delivery, indefinite-quantity or IDIQ agreement for Clinical Trial Planning and Execution or CTPE services with application possibilities encompassing Phases I-IV. The contract has a minimum performance period of two years, stretching to a maximum of five years, with a $250 million total contract ceiling value.
"We are pleased to have been selected by BARDA to support medical countermeasure development and the fight against emerging infectious diseases," said Jason Ezzelle, Pharm-Olam's chief commercial and government contracts officer. "This agreement is the result of our focused investment in our infectious disease business, and further builds upon our growing federally-funded clinical trials portfolio, including support for Operation Warp Speed."
Pharm-Olam holds a membership in the Medical CBRN Defense Consortium and has a history of MCM collaboration with a variety of government entities, including HHS' Centers for Disease Control and Prevention, National Institutes of Health and BARDA, as well as the Department of Defense and several non-governmental organizations.
Pharm-Olam's contract with BARDA is an indefinite-delivery, indefinite-quantity or IDIQ agreement for Clinical Trial Planning and Execution or CTPE services with application possibilities encompassing Phases I-IV. The contract has a minimum performance period of two years, stretching to a maximum of five years, with a $250 million total contract ceiling value.
"We are pleased to have been selected by BARDA to support medical countermeasure development and the fight against emerging infectious diseases," said Jason Ezzelle, Pharm-Olam's chief commercial and government contracts officer. "This agreement is the result of our focused investment in our infectious disease business, and further builds upon our growing federally-funded clinical trials portfolio, including support for Operation Warp Speed."
Pharm-Olam holds a membership in the Medical CBRN Defense Consortium and has a history of MCM collaboration with a variety of government entities, including HHS' Centers for Disease Control and Prevention, National Institutes of Health and BARDA, as well as the Department of Defense and several non-governmental organizations.
